Table 3 Case reports of benralizumab for the management of ICEP

30 mg every 4 weeks for 3 doses then every 8 weeks

1

8 months

Male, 16 years old. Cortico dependent evolution, weight gain, muscle weakness

Symptom improvement immediately after onset

No relapses after initiation

OS dose was reduced after 4 months, then stopped

Not described

Improvement after the start ^a

Improvement after the start ^a

No adverse events during handling

David, Y. et al. 2021 [22].

Single dose, no dose mentioned

1

9

months

Female, 43 years old. Smoker: 10 cigarettes/day. Relapse, refused restarting systemic corticosteroids

Improvement after administration in the first week

None after start

They did not indicate him, only biological

Significant improvement at one month

Not described

Not described

Not described

Izumo et al. 2020 [23].

30 mg single dose

1

4

months

Female, 58 years old. Severe asthma, eosinophilic otitis media. Frequent relapses. Did not undergo LBA

Symptom improvement at 2 weeks, asymptomatic at 8 weeks

None after start

Not indicated, the biological was started

Improvement at 2 weeks with complete resolution at 8 weeks

FENO reduction at 2 weeks (102 vs. 82)

Not described

Not described

Isomoto et al. 2020 [24].

30 mg every 4 weeks, for 3 doses

1

3 months

Female, 31 years old. Did not undergo LBA. Did not accept treatment with a systemic steroid

Improvement at 2 weeks

None after start

They did not indicate him, only biological

Normalization at 5 weeks

Not described

Not described

Not described

Izhakian et al. 2022 [25].

30 mg every 4 weeks for 3 doses, then 30 mg every 8 weeks

1

24 months

Female, 52 years old. Asthma: multiple relapses

Complete improvement with ACT at 2 months

None after initiation of treatment. Sustained clinical and radiological improvement at 6, 9, and 24 months of follow-up

Allows reduction of corticosteroid 2 months after starting treatment

Complete resolution at 7 months (TC)

Normalization 5 months after treatment

Not described

No adverse events during handling

Angeletti et al. 2022 [26].

Do not describe

1

Not described

Female, 83 years old. Severe asthma, eosinophilic bronchiolitis

Improvement after the start ^a

None after start ^a

Tolerated descent and withdrawal ^a

Resolution after treatment ^a

Improvement after the start ^a

Improvement ^a

No adverse events during handling

Takano et al. 2021 [27].

30 mg every 4 weeks for 3 doses, then 30 mg every 8 weeks

1

30 months

Male, 57 years old. Asthma, allergic rhinitis, eczema, anxiety, depression, prostate hypertrophy. Cortico dependence, type 2 diabetes, osteopenia

Improvement after the start. ^a

None after the start. Continued with management without relapses

Reduction at 3 weeks

Resolution after treatment ^a

Improvement after treatment ^a

Not described

Not described

Ricketti & Ricketti 2021 [28].

30 mg every 4 weeks

1

12 months

Female, 70 years old. Severe asthma

Improvement a week

None after start

Not indicated. The biological was started

Improvement after a week, with complete resolution at 4 weeks

Improvement at 4 weeks after handling

Not described

No adverse events during handling

Yazawa et al. 2021 [29].

Not mentioned

1

Not described

Male, 57 years old. Smoker, 20 pack-years. Cortico dependent

Improvement after the start ^a

Not described

Not described

Not described

Not described

Not described

Not described

Braga et al. 2020 [30].

30 mg every 4 weeks

1

Not described

Female, 31 years old. Steroid-induced diabetes, Cushing syndrome, oxygen requirement

Improvement within a week (less need for oxygen)

Not described

Not described

Not described

Not described

Not described

Not described

Garcia-Saucedo et al. 2019 [31].